EL7.AI
StocksMedium•8 September 2026•
1 min read

Inhibrx Reports Positive Phase 2 Data for HNSCC, Eyeing Accelerated Approval

Key Facts

1INBRX-106 plus pembrolizumab showed a 48.3% response rate compared to 26.5% for pembrolizumab alone.
2The interim median progression-free survival (PFS) reached 9.6 months in the randomized Phase 2 study.
3Inhibrx plans to expand the study by 50 patients, potentially serving as a pathway to accelerated approval.

In a move reflecting the rapid advancements in oncological biotechnology, Inhibrx Biosciences has announced positive primary endpoint results from its Phase 2 HexAgon study. The combination of INBRX-106 and pembrolizumab demonstrated a confirmed objective response rate of 48.3%, nearly doubling the 26.5% rate observed in the monotherapy control arm. According to reports, this marks the first OX40 agonist to demonstrate clinical benefit in a randomized controlled trial.

Clinical data revealed that the interim median progression-free survival (PFS) reached 9.6 months for the combination therapy, significantly outperforming the 4.9 months recorded for the control group. Inhibrx plans to expand the study by adding 50 additional patients, a strategic move intended to strengthen the data package for a potential pathway toward accelerated regulatory approval.

Regarding market performance, updated price levels for INBX were unavailable at the close of September 8, 2026, though the strong clinical data places the stock in focus for biotech investors. Looking ahead, market participants are monitoring upcoming US economic catalysts, including the JOLTs Job Openings and the ISM Manufacturing PMI, which may influence broader market sentiment.